https://ansm.sante.fr/informations-de-securite/zelboraf-cotellic-v-rappel-du-risque-datteintes-opthalmiques-et-de-leur-prise-en-charge 2018 false false false France French pharmacovigilance note retinal diseases vision disorders cobimetinib continuity of patient care mass screening risk guidelines for drug use pharmacovigilance uveitis cobimetinib indoles sulfonamides azetidines piperidines Vemurafenib
--- http://www.has-sante.fr/portail/jcms/c_2620147/fr/cotellic http://www.has-sante.fr/portail/jcms/c_2620147/fr/cotellic-cobimetinib-anti-mek-inhibiteur-de-proteine-kinase 2016 false false false France French cobimetinib cobimetinib vemurafenib melanoma neoplasm metastasis administration, oral MAP kinase kinase 1 antineoplastic agents antineoplastic agents adult continuity of patient care treatment outcome antineoplastic combined chemotherapy protocols melanoma BRAF gene mutation evaluation of the transparency committee Metastatic Melanoma Unresectable Malignant Neoplasm guidelines for drug use cobimetinib Tyrosine Kinase Inhibitors cobimetinib cobimetinib azetidines piperidines azetidines piperidines indoles sulfonamides Vemurafenib
--- https://www.ema.europa.eu/medicines/human/EPAR/Cotellic 2015 false false false United Kingdom French English summary of product characteristics package leaflet cobimetinib cobimetinib vemurafenib melanoma neoplasm metastasis administration, oral MAP kinase kinase 1 antineoplastic agents antineoplastic agents adult continuity of patient care drug evaluation syndication feed drug approval europe treatment outcome drug interactions pregnancy breast feeding product surveillance, postmarketing antineoplastic combined chemotherapy protocols melanoma BRAF gene mutation cobimetinib Cobimetinib/Vemurafenib Regimen Tyrosine Kinase Inhibitors cobimetinib cobimetinib azetidines piperidines azetidines piperidines indoles sulfonamides Vemurafenib